Medical news today: Sunday, November 15, 2026
WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
Get tomorrow's issue in your inbox.
- 01
World Prematurity Day 2026 puts the focus on follow-up after neonatal intensive care
Source: World Health Organization
For World Prematurity Day on November 15, WHO's 2026 campaign highlights continued care after a preterm baby leaves a special newborn care unit or NICU. WHO estimates about 15 million babies are born preterm each year, around one in ten births, and calls for coordinated follow-up that includes health and developmental assessments, parental support and specialist services when needed. From 2026 the observance moves from November 17 to November 15 on WHO's calendar.
Why it mattersDischarge is a transition, not the end of care: follow-up systems can help identify developmental and health needs and support families after hospitalisation. This is a public-health campaign focus, not a new clinical practice guideline. More on Infectious disease →
- 02
WHO issues its first type 1 diabetes management guideline for adults
Source: World Health Organization
WHO issued its first adult type 1 diabetes guideline on November 14, designed for routine, low-resource, emergency and humanitarian settings. It recommends intensified insulin therapy with multiple daily injections and dose adjustment according to blood glucose, identifies human insulin as an effective lower-cost option, and recommends regular glucose monitoring; urine glucose testing may be considered where blood testing is unavailable. WHO estimates about 9.5 million people lived with type 1 diabetes globally in 2025.
Why it mattersThe guideline gives health systems a framework for improving access to insulin and glucose monitoring, including where services are disrupted or resources are limited. It is population-level guidance for care systems and clinicians, not individual treatment advice. More on Approvals & regulatory →
- 03
Novo reports 6.2% average three-month weight loss among people who stayed on oral Wegovy
Source: Reuters
Reuters reports company-presented real-world data from 5,872 adults using Novo Nordisk's daily oral Wegovy on the Ro telehealth platform: participants who remained on treatment for the full three months lost an average of 6.2% of starting body weight. The analysis is observational, limited to people who stayed on treatment and was due to be presented at ObesityWeek; it is not a randomised comparison and does not show what all people starting treatment can expect.
Why it mattersThe report adds an early view of real-world use of oral semaglutide, but retention-based results can overstate outcomes for everyone who starts treatment. It is company-reported evidence, not a new regulatory decision or a substitute for longer-term comparative data. More on Approvals & regulatory →
- 04
Madhya Pradesh FDA warns against two imported skin-lightening creams over mercury concerns
Source: The New Indian Express
The New Indian Express reports that Madhya Pradesh's Food and Drug Administration issued a public alert on November 14 advising residents not to buy or use Gori Beauty Cream and Chandni Whitening Cream. The state notice says the products contain heavy metals, notably mercury, above permitted limits and lack the required import registration; officials also seized about 300 packets of Gori Beauty Cream in Indore. The article says CDSCO/DCGI had previously flagged the products to the state in September.
Why it mattersThis is a state-level regulatory alert and local enforcement action, not evidence of a new nationwide ban. It reinforces the importance of checking cosmetic import and licence details and avoiding unregistered products with reported heavy-metal contamination. More on Approvals & regulatory →
- 05
WHO publishes its first type 1 diabetes guideline for children and adolescents
Source: World Health Organization
WHO published its first guideline on diagnosis, management and follow-up of type 1 diabetes in children and adolescents up to age 19. It covers clinical assessment, insulin types and regimens, delivery devices, glucose monitoring, recognition and management of diabetic ketoacidosis and hypoglycaemia, and risk-based screening for retinopathy and nephropathy, with particular attention to primary care and resource-limited settings.
Why it mattersThe guidance aims to reduce gaps in paediatric diabetes care and support more consistent recognition of emergencies and long-term complications. Implementation will depend on local resources, training, insulin supply and national protocols. More on Approvals & regulatory →
- 06
JAMA study finds a candidate blood biomarker signal in advanced CTE, but not early disease
Source: JAMA
A JAMA case-control study of 229 participants found that fluid eMTBR-tau243 was elevated in several mixed 3-repeat/4-repeat tauopathies, including Alzheimer disease, advanced chronic traumatic encephalopathy (CTE) and a subset of genetic frontotemporal lobar degeneration. Plasma results were available for only 11 people with CTE: the marker distinguished stage III/IV cases from controls in this small sample but did not reliably identify stage I disease. The authors call for larger independent validation cohorts.
Why it mattersThe findings are an early biomarker research signal, not a validated blood test for diagnosing CTE in living people. The marker is also elevated in other tau-related diseases, so it cannot be treated as CTE-specific or used as a standalone diagnostic. More on Neurology →
- 07
ACAAI conference study links dupilumab treatment for childhood EoE with fewer later asthma diagnoses
Source: American College of Allergy, Asthma and Immunology
An ACAAI 2026 meeting abstract describes a retrospective health-record cohort of children aged six or younger with eosinophilic oesophagitis (EoE) and no prior asthma. Among 344 children treated with dupilumab and 401 treated with swallowed budesonide, incident asthma was recorded in 10.5% and 16.2%, respectively, after matching on selected baseline characteristics. The conference report says the association does not prove dupilumab prevents asthma and calls for further research.
Why it mattersThis is hypothesis-generating observational evidence presented at a scientific meeting, not proof of prevention or a new approved indication. Confounding and differences in follow-up or asthma recognition may affect the association, so prospective studies are needed. More on Approvals & regulatory →
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
- Wednesday, November 11, 2026FDA approves pimicotinib; GLP-1 eye warning and two device alerts; WHO updates TB resistance catalogue
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
